Form 8-K - Current report:
SEC Accession No. 0001193125-25-061872
Filing Date
2025-03-25
Accepted
2025-03-25 06:38:54
Documents
13
Period of Report
2025-03-25
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d936530d8k.htm   iXBRL 8-K 28811
  Complete submission text file 0001193125-25-061872.txt   152903

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mura-20250325.xsd EX-101.SCH 2868
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mura-20250325_lab.xml EX-101.LAB 17910
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mura-20250325_pre.xml EX-101.PRE 11246
15 EXTRACTED XBRL INSTANCE DOCUMENT d936530d8k_htm.xml XML 3610
Mailing Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380
Business Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380 353 1 905 8020
Mural Oncology plc (Filer) CIK: 0001971543 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41837 | Film No.: 25765729
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)